We observed that geldanamycin partially induced synthetic lethality with FHIT loss in lung cancer cells, accompanied by the downregulation of BRCA1 and RAD51 levels (Supplementary Fig. 7a, c). The gene discussed is RAD51; the disease is lung carcinoma.